AAV-Mediated CLRN1 Gene Delivery for Hearing and Vision Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hearing and vision loss, such as nonsyndromic deafness and retinitis pigmentosa, lack effective methods for repairing or mitigating the underlying cellular damage, particularly in the inner ear and retina, where hair cells and photoreceptor cells are affected, leading to permanent loss.
Innovation Solution
Administration of compositions expressing gene products, specifically encoded by the CLRN1 gene, using AAV particles to promote the development, function, and maintenance of inner ear and eye cells, including hair cells and supporting cells, through surgical delivery methods like the round window membrane injection, facilitating tissue-specific expression and potential regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for hearing and vision loss are used, then existing therapeutic methods are available, but effective repair or mitigation of underlying cellular damage is lacking
Solution Approach 1:
The patent uses adeno-associated virus (AAV) particles as intermediary vectors to deliver CLRN1 gene products to target cells in the inner ear and retina. This viral vector system serves as a mediator between the therapeutic gene and the target tissue, enabling effective delivery where previous treatments failed to achieve cellular repair.
Solution Approach 2:
The patent employs the body's own cellular machinery to produce the therapeutic clarin 1 protein by delivering the CLRN1 gene through AAV vectors. Once the gene is delivered, host cells self-service by transcribing and translating the gene into functional protein, eliminating the need for continuous external administration of the therapeutic protein.
2Adaptability or versatility
If gene therapy approaches are implemented, then potential for cellular regeneration is achieved, but delivery methods and tissue-specific expression challenges arise
Solution Approach 1:
The patent uses a universal AAV vector system that can deliver the CLRN1 gene to multiple target tissues including both inner ear hair cells and retinal photoreceptors. This multi-functional vector approach enables the same delivery mechanism to address both hearing and vision loss associated with CLRN1 mutations, simplifying the overall therapeutic strategy.
Solution Approach 2:
The patent achieves tissue-specific expression by combining localized delivery methods (intra-cochlear injection for ear, subretinal injection for eye) with tissue-specific promoter elements in the AAV construct. This ensures the CLRN1 gene is expressed specifically in target cells (hair cells and photoreceptors) while minimizing off-target effects.
3Reliability
If permanent hair cell damage is addressed, then potential for hearing restoration is achieved, but current inability to repair damaged cells remains
Solution Approach 1:
The patent applies preliminary action by delivering the CLRN1 gene through AAV vectors before complete cell death occurs, or early in the disease progression. This preventive approach allows the therapeutic protein to be produced while cells are still viable and capable of responding to the restored gene function, potentially preventing permanent damage rather than attempting to reverse it.
Solution Approach 2:
The patent converts the harmful effect of CLRN1 gene mutations (which cause cell death) into a benefit by delivering a functional copy of the gene through AAV vectors. The same genetic defect that causes harm is addressed by using the viral vector system to restore normal gene function, transforming the pathological condition into a treatable state.
Data Source
AI summary
The present disclosure provides constructs comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a clarin 1 protein. Exemplary constructs include AAV constructs. Also provided are methods of using disclosed constructs for the treatment of hearing loss and/or deafness. Also provided are methods of using disclosed constructs for the treatment of vision loss.